Search results for " PEG"

showing 10 items of 88 documents

Inulin-based polymer coated SPIONs as potential drug delivery systems for targeted cancer therapy

2014

This paper deal with the synthesis and characterization of PEGylated squalene-grafted-inulin amphiphile capable of self-assembling and self-organizing into nanocarriers once placed in aqueous media. It was exploited as coating agent for obtaining doxorubicin loaded superparamagnetic iron oxide nanoparticles (SPIONs) endowed with stealth like behavior and excellent physicochemical stability. Inulin was firstly modified in the side chain with primary amine groups, followed in turn by conjugation with squalenoyl derivatives through common amidic coupling agents and PEGylation by imine linkage. Polymer coated SPIONs were so obtained by spontaneous self-assembling of inulin copolymer onto magnet…

Hydrodynamic radiusCell SurvivalPolymersSurface PropertiesPharmaceutical ScienceTherapeutic indexSpectroscopy Fourier Transform InfraredAmphiphileZeta potentialmedicineSPIONs Inulin copolymer Doxorubicin Magnetic targeting Squalene PegylatedHumansOrganic chemistryDoxorubicinParticle SizeMagnetite NanoparticlesDrug CarriersAntibiotics AntineoplasticMolecular StructureChemistryInulinGeneral MedicineHCT116 CellsCombinatorial chemistryDrug LiberationDoxorubicinDrug deliveryMicroscopy Electron ScanningPEGylationNanocarriersBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Convergence and divergence in organization of phytoplankton communities under various regimes of physical and biological control

2010

The hypothesis that physical constraints may be as important, if not more important, than biological ones in shaping the structure of phytoplankton assemblage was tested by analyzing longterm (11–29 years) phytoplankton series in eight lakes and nine sites located along a latitudinal gradient in the Northern hemisphere. Phytoplankton biomass was used and similarity of assemblages in same months of the annual data sets was then calculated by subtracting the Bray–Curtis dissimilarity index from 1. The extent of biological and physical forcing was partly based on ‘‘expert evaluation’’: the importance of four physical (light availability, temperature, conductivity, and sediment stirring up) and…

Index of dissimilarityBiomass (ecology)EcologyPhytoplanktonTemperate climateNorthern HemisphereEcosystemPhytoplankton biomass Phytoplankton composition Similarity PEG model Biological control Ecosystem functioningForcing (mathematics)Physical geographyAquatic SciencePlanktonBiologyHydrobiologia
researchProduct

Gozos al Santisimo Ecce-Homo, venerado en el Hospital de la villa de Pego.

El full orlat Grav. xil. enmarcat del Ecce-Homo, flanquejat per gerros amb flors Text del goig a tres col. separades per filets

Jesucrist GoigsDevocions populars Comunitat Valenciana PegoHospital de PegoEcce-Homo Goigs
researchProduct

Gozos al Santisimo Ecce-Homo, venerado en el Hospital de la villa de Pego.

El full orlat Grav. xil. enmarcat del Ecce-Homo, flanquejat per gerros amb flors Text del goig a tres col. separades per filets

Jesucrist GoigsDevocions populars Pego (Comunitat Valenciana)Hospital de PegoEcce-Homo Goigs
researchProduct

Gozos al Santisimo Ecce-Homo, venerado en el Hospital de la villa de Pego

1750

El full orlat Grav. xil. enmarcat del Ecce-Homo, flanquejat per gerros amb flors Text del goig a tres col. separades per filets

Jesucrist GoigsHospital de PegoEcce-Homo GoigsDevocions populars Pego (Comunitat valenciana)
researchProduct

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

2016

Background: Iron overload and hepatitis C virus (HCV) infection together can lead to chronic liver damage in thalassemia major (TM) patients. Aims: We investigated viral, genetic, and disease factors influencing sustained virological response (SVR) after peg-interferon and ribavirin therapy in TM patients with HCV infection. Methods: We analyzed 230 TM patients with HCV infection (mean age 36.0 ± 6.3 years; 59.1% genotype 1; 32.2% genotype 2; 3.4% genotype 3; and 5.3% genotype 4; 28.7% carried CC allele of rs12979860 in IL28B locus; 79.6% had chronic hepatitis and 20.4% cirrhosis; 63.5% naive and 36.5% previously treated with interferon alone) treated in 14 Italian centers. Results: By mul…

Liver Cirrhosis0301 basic medicineMaleCirrhosisThalassemiaHepacivirusCirrhosis; Hepatitis C virus; IL28B polymorphisms; Iron liver overload; Peg-interferon; Ribavirin; Sustained virological response; Thalassemia major; Adult; Antiviral Agents; Drug Therapy Combination; Female; Heart Diseases; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Interleukins; Italy; Liver Cirrhosis; Logistic Models; Male; Multivariate Analysis; Polymorphism Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; beta-Thalassemiamedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRetrospective StudieThalassemia majorMultivariate AnalysiGastroenterologyBeta thalassemiaHepatitis CViral LoadSustained virological responseHeart DiseaseTreatment OutcomeItaly030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyHeart DiseasesLogistic ModelHepatitis C virusLiver CirrhosiAlpha interferonIL28B polymorphismAntiviral AgentsPolymorphism Single Nucleotide03 medical and health sciencesIron liver overloadInternal medicineRibavirinmedicineHumansRetrospective StudiesAntiviral AgentCirrhosiHepaciviruPeg-interferonHepatologybusiness.industryInterleukinsRibavirinbeta-ThalassemiaInterferon-alphaHepatitis C ChronicInterleukinmedicine.diseaseLogistic Models030104 developmental biologychemistryMultivariate AnalysisImmunologyInterferonsbusinessHepatitis C viru
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

Treatment of hepatitis C: critical appraisal of the evidence

2005

Chronic hepatitis C virus infection is currently the most common cause of end stage liver disease worldwide. Although the conclusions of the last National Institutes of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues remain unanswered. This paper reviews the available data using an evidence-based approach. Current evidence is sufficient to recommend IFN treatment for all patients with acute hepatitis. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during month 1 is the best treatment option. The current gold standard of efficacy for treatment-naive patients with ch…

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularCirrhosisInterferon alpha-2Antiviral AgentsPolyethylene Glycolschemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicinemedicineHumansPharmacology (medical)Randomized Controlled Trials as TopicPharmacologybusiness.industrycombination treatment hepatitis C histological benefit meta-analysis pegylated interferonRibavirinLiver NeoplasmsInterferon-alphaGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CRecombinant ProteinschemistryTolerabilityHepatocellular carcinomaMeta-analysisAcute DiseaseImmunologybusinessmedicine.drug
researchProduct

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

Multifunctional Poly(ethylene glycol)s

2011

In the rapidly evolving multidisciplinary field of polymer therapeutics, tailored polymer structures represent the key constituent to explore and harvest the potential of bioactive macromolecular hybrid structures. In light of the recent developments for anticancer drug conjugates, multifunctional polymers are becoming ever more relevant as drug carriers. However, the potentially best suited polymer, poly(ethylene glycol) (PEG), is unfavorable owing to its limited functionality. Therefore, multifunctional linear copolymers (mf-PEGs) based on ethylene oxide (EO) and appropriate epoxide comonomers are attracting increased attention. Precisely engineered via living anionic polymerization and d…

LymphomapolyethersNanotechnologyAntineoplastic AgentsPolyethylene glycolMolecular-WeightCatalysisPolyethylene Glycolschemistry.chemical_compoundepoxidesCopolymerOrganic chemistryAnimalsLiving anionic polymerizationchemistry.chemical_classificationWeight Hyperbranched PolyglycerolsDrug CarriersDrug-Delivery SystemsEthylene oxidepoly(ethylene glycol)Ethylene-OxideGene Transfer TechniquesPolymer TherapeuticsGeneral ChemistryPolymermultivalencybioconjugatesPendant Amino-GroupsPolyethylene-GlycolchemistryPolymerizationAnionic Peg DerivativesDoxorubicinBlock-CopolymersCisplatinIn-VivoDrug carrierPeptidesEthylene glycol
researchProduct